The APSFA is looking for people to submit their photos for "The Faces of APS". Details in the .pdf linked below. Please help us bring awareness to this disease to main stream media!
Deadline: January 4, 2010
http://www.apsfa.org/docs/Faces%20of%20APS.pdf
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS, faces
Sunday, December 06, 2009
Faces of APS - The APSFA Needs YOUR Help!
Saturday, November 21, 2009
FALL/WINTER 2009 volume of our quarterly newsletter, "Antiphospho...What??" is Available
The FALL/WINTER 2009 volume of our quarterly newsletter, "Antiphospho...What??" is ready to be downloaded. You can download it at the following link: http://www.apsfa.org/docs/APSFAVol15FallWinter2009.pdf
The next volume will be coming out in late Winter, early Spring, 2010.
Please let us know if there are any topics that you'd like our Medical Advisors to cover in their articles. We try to request topics that people are emailing about or that are discussed on our the forum. So if there's anything you'd like to see, please let us know and we'll pass it along to the medical advisors.
We are still in need of patient stories (esp about Pregnancy Loss, Men and Teens or Children), recipes, poems, related book reviews, and anything else you think would be of interest for upcoming newsletters. (book reviews, poems, recipes, articles written by family members, etc.) Please submit articles to the following email address: articles@apsfa.org.
If you have an idea and are not sure if it would fit, please feel free to contact us through our contact page on the website, or email us using the email address below. We are open to any suggestions. Without your help we would not be able to include an APS patient's story in each of our newsletters.
We could also use articles written by medical professionals or medical students. Please contact us if you are interested.
Please remember to check our website for any changes at the following link: http://www.apsfa.org/new.htm
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS, newsletter
Monday, November 16, 2009
*Exclusive* 2009 APSFA Holiday Ornament
Our EXCLUSIVE holiday snowflake ornament is now available for purchase in our Cafepress store. This is the 4th in the series and each one is unique! We picked the snowflake to be the symbol on this special ornament because like there are no two snowflakes that are alike, no two APS patients are alike!
Purchase this ornament here: http://www.cafepress.com/apsfoundation/1952386
Purchase this ornament here: http://www.cafepress.com/apsfoundation/1952386
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS, holiday, ornament
Sunday, November 15, 2009
2009 APSFA Giving Tree
We are excited to announce the arrival of our 4th Annual Holiday Giving Tree!
This tree holds a special meaning for the members of the APS Foundation of America, Inc and the community it serves. Since the Giving Tree has been such a big success in the past, we've made it an annual tradition.
How the tree works: When you make a donation using the chart below the tree, you get to chose an ornament or present that coincides with the amount you wish to donate. We will then trim the tree with the ornaments selected. By the end of the season we will have a beautifully decorated tree due to your generous donations!
As in the past, the ornaments are one of a kind and we even have new presents this year!
All Giving Tree donations are tax deductible and need to be made by 12/31/09 to be included for 2009.
Thank you for your consideration and generosity this holiday season!
To make a donation and add an ornament to our tree click here: http://www.apsfa.org/givingtree.htm
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS, giving treeFriday, November 13, 2009
`Wipeout' TV show player with rare condition dies
`Wipeout' TV show player with rare condition dies
Thu Nov 12, 7:03 pm ET
LOS ANGELES – A contestant who was hospitalized after competing briefly on the game show "Wipeout" died two weeks later of a stroke apparently caused by a rare condition, his father said.
Tom Sparks, 33, was participating in the first segment of an obstacle course Oct. 19 when he complained of knee pain, according to Endemol, the company which produces "Wipeout" for ABC.
Producers had him stop, Endemol said Thursday. On-set medics examined Sparks, noticed he was short of breath and took him to a local hospital.
He was moved to Cedars-Sinai Medical Center and underwent several brain surgeries, according to TheWrap.com, which first reported Sparks' Nov. 5 death.
Sparks couldn't be saved because of the brain damage that had occurred, the Web site said, citing an e-mail to alumni from a faculty member at Sparks' alma mater.
Sparks, a former Sun Valley, Idaho, radio disc jockey, earned a bachelor's degree from the University of Southern California and later earned a master's degree from the USC Annenberg School for Communication & Journalism.
In a statement to the Idaho Mountain Express and Guide, Bill Sparks, his father, said doctors determined the stroke probably was caused by antiphospholipid antibody syndrome, known as APS.
APS is associated with recurrent clotting events including premature stroke and heart attack, according to the APS Foundation of America Inc.'s Web site.
"Wipeout" contestants undergo medical examinations before they are cleared for the show, Endemol said. However, the diagnosis of APS requires specialized blood tests, the foundation said on its site.
"We offer our heartfelt condolences to the family," ABC and Endemol said in a joint statement. "This is a tragic loss and our thoughts are with them at this time."
Sparks, who was a runner and recently competed in a marathon, had just married and was competing on "Wipeout" with his wife, Kate, on a couples episode. The show is in production for the third season, premiering next summer.
___
On the Net:
http://www.apsfa.org/
http://www.abc.go.com
Story URL: http://news.yahoo.com/s/ap/20091113/ap_en_tv/us_tv_wipeout_player_dies
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS, wipeout, tom sparks
Friday, October 23, 2009
2009 H1N1 Flu (referred to as “swine flu” early on) and Seasonal Flu Information for People with Inflammatory Arthritis or Rheumatic Disease
2009 H1N1 Flu (referred to as “swine flu” early on) and Seasonal Flu Information for People with Inflammatory Arthritis or Rheumatic Disease
October 15, 2009, 11:00 AM ET
How does arthritis affect how I respond to the flu?
People with certain types of arthritis, called inflammatory or systemic arthritis or autoimmune rheumatic disease, have a higher risk of getting flu-related complications, such as pneumonia. Inflammatory arthritis affects the immune system which controls how well your body fights off infections. Also, many medications given to treat inflammatory arthritis can weaken the immune system. People with weakened immune systems are at high risk for getting more severe illness and complications such as hospitalization with the flu. Rheumatoid arthritis and lupus are the most common types of inflammatory arthritis.
People with osteoarthritis, also called degenerative arthritis, are likely not at increased risk of complications from the flu unless they also have other high-risk conditions for flu such as asthma, diabetes, heart disease, or cancer.
If you have one of these types of inflammatory arthritis, you may be at high risk for complications from the flu. You should discuss your risk for complications from the flu with your healthcare provider.
Types of Inflammatory Arthritis |
|
If you are taking one or more of these medications for your arthritis, you may be at high risk for getting the flu or complications from the flu. Note: This list applies to medications that are ingested or injected and does NOT include medications that are applied to the skin such as creams and ointments. Your healthcare provider can clarify if the medications that you take weaken the immune system.
Arthritis medications that weaken the immune system |
|
What are the symptoms of the flu?
The symptoms of 2009 H1N1 flu virus in people are similar to the symptoms of seasonal flu and include fever, cough, sore throat, runny or stuffy nose, body aches, headache, chills, and fatigue. Some people may have vomiting and diarrhea. People may be infected with the flu, including 2009 H1N1, and have respiratory symptoms without a fever.
How can I avoid getting and the flu or giving the flu to others?
The flu is spread from person-to-person by coughing or sneezing by people with influenza. Sometimes people may become infected by touching something – such as a surface or object – with flu viruses on it and then touching their mouth or nose. You can take simple actions to protect yourself and others from getting the flu:
- Get a seasonal flu shot now and the 2009 H1N1 flu shot when it becomes available.
- Cover your nose and mouth with a tissue when you cough or sneeze. Throw the tissue in the trash after you use it.
- Wash your hands often with soap and water, especially after you cough or sneeze. Alcohol-based hand cleaners are also effective.
- Avoid touching your eyes, nose, or mouth. Germs spread this way.
- Try to avoid close contact with sick people.
- If you are sick with flu-like illness, seek medical care early. Your health care provider can determine if you need to be treated with antiviral medication.
- Keep away from others as much as possible to keep from making others sick. CDC recommends that you stay home for at least 24 hours after your fever is gone except to get medical care or for other necessities. Your fever should be gone without the use of a fever-reducing medicine.
Is there a vaccine against the 2009 H1N1 flu virus and who is it available for?
Yes. A vaccine for the 2009 H1N1 flu has been developed and will be available beginning mid-October 2009. People with inflammatory arthritis within any of the following prioritized groups are recommended to receive the 2009 H1N1 vaccine when it first becomes available:- Pregnant women
- People who live with or care for children younger than 6 months of age
- Healthcare and emergency medical services personnel
- Persons between the ages of 6 months and 24 years old
- Persons between the ages of 25 and 64 years old who are at higher risk for 2009 H1N1 because of chronic health disorders or compromised immune systems (including with inflammatory arthritis)
Persons age 65 or older (including those with inflammatory arthritis) are not included in these prioritized groups because current studies indicate that the risk for 2009 H1N1 flu infection among persons age 65 or older is less than the risk for younger age groups. We do not expect that there will be a shortage of 2009 H1N1 vaccine, but availability and demand can be unpredictable. Once the demand for vaccine among the younger groups has been met, however, people age 65 or older with inflammatory arthritis should receive the 2009 H1N1 flu shot.
Do I need to get a flu shot?
Yes, CDC recommends certain persons with weakened immune systems, which includes people with inflammatory arthritis, get flu shots.
People with inflammatory arthritis should get—
- A seasonal flu shot every year. These are available beginning in September.
- The new 2009 H1N1 flu shot when available (see question above). These will begin to be available in mid-October 2009.
People living with inflammatory arthritis should get the "flu shot"— an inactivated vaccine (containing fragments of killed influenza virus) that is given with a needle, usually in the arm. The flu shot is approved for use in people inflammatory arthritis.
The other type of flu vaccine — nasal-spray flu vaccine (sometimes called LAIV for “live attenuated influenza vaccine)—is not currently approved for use in people with inflammatory arthritis. This vaccine is made with live, weakened flu viruses that do not cause the flu). LAIV (FluMist®) is approved for use in healthy people 2-49 years of age.
What should I do when I am sick?
- If you develop flu-like symptoms contact your healthcare provider.
- Avoid contact with others. You should stay home and avoid travel, including not going to work or school, until at least 24 hours after your fever is gone except to get medical care or necessities. Your fever should be gone without using fever-reducing medications.
- If you leave the house to seek medical care, wear a facemask, if available and tolerable, and cover your coughs and sneezes with a tissue.
- Do not stop taking any medicine you take for your arthritis unless told to do so by your physician.
- Seek medical attention early if you develop symptoms of the flu. Treatment is available for persons with severe disease and those at high risk for complications. Persons with inflammatory arthritis are considered high risk for complications from the flu; therefore, your health care provider may choose to prescribe antiviral medications for you if you get the flu.
- If you are exposed to someone who has flu, consult your health care provider. They may prescribe medication to help prevent you from getting the flu or watch you closely to see if you develop flu symptoms.
For more information:
H1N1 Flu: General information
http://www.cdc.gov/h1n1flu/general_info.htm
Arthritis Foundation Flu: What People with Arthritis Should Know*
http://www.arthritis.org/the-flu.php
H1N1 Advisory for People with Lupus*
http://www.lupus.org/webmodules/webarticlesnet/templates/new_empty.aspx?articleid=2681&zoneid=99
Lupus and Influenza Vaccines*
http://www.lupus.org/webmodules/webarticlesnet/templates/new_learnliving.aspx?articleid=2688&zoneid=527
* Links to non-Federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the Federal Government, and none should be inferred. The CDC is not responsible for the content of the individual organization Web pages found at this link.
http://www.cdc.gov/h1n1flu/arthritis.htmKeywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS, H1N1, flu, swine
Sunday, October 18, 2009
13th International Congress on Antiphospholipid Antibodies
13th International Congress on Antiphospholipid Antibodies
"Antiphospholipid by the Beach"
Four days of the most up-to-date evidence-based medicine and state-of-the-art scientific sessions on Antiphospholipid Antibodies and the Antiphospholipid syndrome.
Participants included: rheumatologists, hematologists, OB-Gyn specialists, neurologists, dermatologists, cardiologists, pathologists, researchers, laboratory scientists and clinicians dealing with Antiphospholipid Syndrome, SLE and other related autoimmune diseases.
There will be a patient session on Wednesday April 14 & 15, 2010 from 5:00-6:30PM CT
URL for more information on costs, hotels & location here: http://www.utmb.edu/apla2010
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS, APLA, conference, CME, international
Monday, August 17, 2009
Volume 14 of the APSFA Newsletter - "Antiphospho...What?"
Hello!!
The SUMMER/FALL 2009 volume of our quarterly newsletter, "Antiphospho...What??" is ready to be downloaded. You can download it at the following link: http://www.apsfa.org/docs/APSFAVol14SumFall09.pdf
The next volume will be coming out in late Fall, early Winter 2009.
Please let us know if there are any topics that you'd like our Medical Advisors to cover in their articles. We try to request topics that people are emailing about or that are discussed on our the forum. So if there's anything you'd like to see, please let us know and we'll pass it along to the medical advisors.
We are still in need of patient stories (esp about Pregnancy Loss, Men and Teens or Children), recipes, poems, related book reviews, and anything else you think would be of interest for upcoming newsletters. (book reviews, poems, recipes, articles written by family members, etc.) Please submit articles to the following email address: articles@apsfa.org.
If you have an idea and are not sure if it would fit, please feel free to contact us through our contact page on the website, or email us using the email address below. We are open to any suggestions. Without your help we would not be able to include an APS patient's story in each of our newsletters.
Thank you to those people who have submitted articles. If you have submitted an article and we have not used it yet, we will be using it in the near future.
We could also use articles written by medical professionals or medical students. Please contact us if you are interested.
Please remember to check our website for any changes at the following link: http://www.apsfa.org/new.htm
Thank you for your continued support!
Thursday, July 09, 2009
Preventing Miscarriages
On June 25th, Judy Smith did an interview with Fox News in Tampa Bay. Judy has had several miscarriages and at one point thought she had MS. It wasn't until her Dr. did a simple blood test that revealed she had a potentially life threatening illness called APS.
She can not stress the importance of the APS Foundation of America, Inc (http://www.apsfa.org), and how it has played a part in helping her cope with this disease. Not only do they have a support group for others with APS, but they are the only "United States nonprofit health agency dedicated specifically to bringing national awareness to Antiphospholipid Antibody Syndrome (APS), the major cause of multiple miscarriages, thrombosis, and young strokes and heart attacks."
"Knowing more about APS can make all the difference. Get in the Know and Get in the Flow!"
Please watch this video as it may help someone you know.
http://www.myfoxtampabay.com/dpp/health/doctor_jo/Preventing_miscarriages_070809
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS
Monday, June 22, 2009
Signs and Symptoms of Antiphospholipid Antibody Syndrome: Get in the Know and Get in the Flow!
FOR IMMEDIATE RELEASE
Date: 06/22/2009
Contact: Christina "Tina" Pohlman
Phone: 608-782-2626
Website Address: www.apsfa.org
Email Address: apsfa@apsfa.org
Signs and Symptoms of Antiphospholipid Antibody Syndrome: Get in the Know and Get in the Flow!
The Antiphospholipid (APS) Antibody Syndrome Foundation of America, Inc. (APSFA) urges the public, as well as the medical community, to learn more about this rare disease. APS Awareness Month runs throughout June.
APS is an autoimmune disorder. Such illnesses occur when the body’s tissues are attacked by its own substances. In APS, the body recognizes certain components of blood or cell membranes as foreign substances and produces antibodies--a specialized protein the body uses to prevent infection--against them. It is the major cause of strokes in persons under 40 years old, blood clots (thrombosis) – which can lead to heart attack or stroke – vision disturbances and repeated, otherwise unexplainable miscarriages.
While more general practitioners have become familiar with APS in the last few years, many physicians – and most of the public – are still unfamiliar with both its symptoms and the damage it can cause.
People who arrive at emergency rooms and doctor’s offices with the following issues should be tested for APS:
• Heart attacks and strokes in those under 50
• Transient ischemic attacks, known as “mini-strokes.” TIAs last 10 minutes or less and leave no permanent damage.
• Multiple miscarriages and stroke
• Blood clots in the lung (called pulmonary emboli) or deep veins in arms and legs (called deep vein thrombosis, or DVT)
• Diminishing mental alertness, such as loss of concentration, memory loss and difficulty with reading comprehension
• Migraine headaches
• Partial or total vision loss
• Dizziness
• Seizures
APS shares symptoms with more well-known disorders such as multiple sclerosis and lupus. Diagnosis and treatment delays can cause serious, sometimes fatal complications. A simple blood test can determine whether someone has APS.
The APS Foundation of America, Inc. is the only United States health agency dedicated specifically to bringing national awareness to APS. We are a volunteer-run, community-based, non-profit organization dedicated to spreading awareness and support to those with the disease.
Knowing more about APS can make all the difference. Get in the know and Get in the Flow!
For more information Contact: Christina "Tina" Pohlman at Phone: 608-782-2626 Website Address: www.apsfa.org. Email Address: apsfa@apsfa.org
###
Public Service Announcement for Week 4:
http://www.youtube.com/watch?v=GRiK_CncGyU
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS, PSA
Monday, June 15, 2009
APS Often the Culprit Behind Heart Attack and Stroke in Younger Adults
FOR IMMEDIATE RELEASE
Date: 06/15/2009
Contact: Christina "Tina" Pohlman
Phone: 608-782-2626
Website Address: www.apsfa.org
Email Address: apsfa@apsfa.org
APS Often the Culprit Behind Heart Attack and Stroke in Younger Adults
The Antiphospholipid Antibody Syndrome Foundation of America, Inc. (APSFA) urges the public, as well as the medical community, to learn more about this rare disease. APS Awareness Month runs throughout June.
APS is an autoimmune disorder. Such illnesses occur when the body’s tissues are attacked by its own substances. In APS, the body recognizes certain components of blood or cell membranes as foreign substances and produces antibodies--a specialized protein the body uses to prevent infection--against them. It is the major cause of strokes in persons under 40 years old, blood clots (thrombosis) – which can lead to heart attack or stroke – vision disturbances and repeated, otherwise unexplainable miscarriages.
A heart attack generally occurs when a coronary artery clot blocks the supply of blood and oxygen to heart muscle. There are more than one million heart attack sufferers annually in the U.S.; about half of those stricken die. Unfortunately, many heart attack victims wait two hours or more after symptoms begin before they seek medical help. This delay can result in death or lasting heart damage.
A stroke, or "brain attack," occurs when blood circulation to the brain fails. Brain cells can die from decreased blood flow and the resulting lack of oxygen. There are two broad categories of stroke: those caused by a blockage of blood flow (called “ischemic” strokes) and those caused by bleeding. Ischemic strokes account for about 80 percent of all strokes. They usually are not fatal.
A transient ischemic attack, or TIA, is an ischemic stroke that occurs when the brain’s blood supply is interrupted briefly (10 minutes or less). There generally is no lasting damage, but recent research shows that about half of people who experience a TIA have a full-blown stroke within 24 hours.
APS is the leading cause of heart and brain attacks in people under 50. If you have a personal or family history of heart attack or stroke before age 50, ask your primary care physician to test you for APS. It requires only a simple blood test.
The APS Foundation of America is the only United States health agency dedicated specifically to bringing national awareness to APS. We are a volunteer-run, community-based, non-profit organization dedicated to spreading awareness and support to those with the disease.
Knowing more about APS can make all the difference. Get in the know and Get in the Flow!
For more information Contact: Christina "Tina" Pohlman at Phone: 608-782-2626 Website Address: www.apsfa.org Email Address: apsfa@apsfa.org
###
Public Service Announcement for Week 3:
http://www.youtube.com/watch?v=63-5f0G9CCA
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS
Tuesday, June 09, 2009
Press Release: APS Linked to Birth Difficulties (2009)
FOR IMMEDIATE RELEASE
Date: 06/8/2009
Contact: Christina "Tina" Pohlman
Phone: 608-782-2626
Website Address: www.apsfa.org
Email Address: apsfa@apsfa.org
APS Linked to Birth Difficulties
The Antiphospholipid Antibody Syndrome Foundation of America, Inc. (APSFA) urges the public, as well as the medical community, to learn more about this rare disease. APS Awareness Month runs throughout June.
APS is an autoimmune disorder. Such illnesses occur when the body’s tissues are attacked by its own substances. In APS, the body recognizes certain components of blood or cell membranes as foreign substances and produces antibodies--a specialized protein the body uses to prevent infection--against them. It is the major cause of strokes in persons under 40 years old, blood clots (thrombosis) – which can lead to heart attack or stroke – vision disturbances and repeated, otherwise unexplainable miscarriages.
Even otherwise-healthy women are at higher risk of developing blood clots and preeclampsia, a blood pressure disorder that occurs only during pregnancy. In women with APS, blood clots can form in the placenta and starve the baby of nutrition. Placental clots can cause fetal growth problems and distress, premature birth, or miscarriage. Some women with APS have difficulty becoming pregnant at all.
Babies born to women with APS often are delivered between 30 to 35 weeks gestation, or about 5 to 10 weeks early. Low birth weight – between 3 to 5 pounds – is not uncommon, although the babies generally are healthy and thrive after delivery.
Physicians often suggest that women of childbearing age who also are susceptible to blood clots remain indefinitely on a course of low-dose aspirin therapy. Aspirin is a readily available, inexpensive drug to help guard against blood clots. As with gestational diabetes, in which the illness resolves itself once the baby is delivered, it is possible for some women with clotting issues during pregnancy to return to full health post-birth.
APS can be diagnosed with a simple blood test. It frequently is found in conjunction with lupus, another autoimmune disorder that primarily targets women.
Knowing more about APS can make all the difference. Get in the know and Get in the Flow!
The APSFA is the only United States health agency dedicated specifically to bringing national awareness to APS. We are a volunteer-run, community-based, non-profit organization.
For more information Contact: Christina "Tina" Pohlman at Phone: 608-782-2626 Website Address: www.apsfa.org. Email Address: apsfa@apsfa.org
###
Public Service Announcement for Week 2:
http://www.youtube.com/watch?v=z2snb2bXUEI
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS
Monday, June 01, 2009
JUNE IS APS AWARENESS MONTH: GET IN THE FLOW!
FOR IMMEDIATE RELEASE
Date: 06/01/2009
Contact: Christina "Tina" Pohlman
Phone: 608-782-2626
Website Address: www.apsfa.org
Email Address: apsfa@apsfa.org
JUNE IS APS AWARENESS MONTH: GET IN THE FLOW!
The Antiphospholipid Antibody Syndrome (APS) Foundation of America, Inc. (APSFA) urges the public, as well as the medical community, to learn more about this rare disease. APS Awareness Month runs throughout June.
APS is an autoimmune disorder. Such illnesses occur when the body’s tissues are attacked by its own substances. In APS, the body recognizes certain components of blood or cell membranes as foreign substances and produces antibodies--a specialized protein the body uses to prevent infection--against them. It is the major cause of strokes in persons under 40 years old, blood clots (thrombosis) – which can lead to heart attack or stroke – vision disturbances and repeated, otherwise unexplainable miscarriages.
APS often is found in conjunction with lupus, another autoimmune disorder that primarily targets women.
Knowing more about APS can make all the difference. Get in the know and Get in the Flow!
The APSFA is the only United States health agency dedicated specifically to bringing national awareness to APS. We are a volunteer-run, community-based, non-profit organization.
For more information Contact: Christina "Tina" Pohlman at Phone: 608-782-2626
Website Address: www.apsfa.org. Email Address: apsfa@apsfa.org
###
Public Service Announcement for Week 1
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS, PSA
Saturday, May 23, 2009
Antiphospholipid Syndrome (APS) Education
Michael D. Lockshin, MD
Attending Rheumatologist, Hospital for Special Surgery
Professor of Medicine, Weill Cornell Medical College
Director, Barbara Volcker Center for Women and Rheumatic Disease
In this presentation, Dr. Lockshin provides an explanation of antiphospholipid syndrome (APS) and how it can be treated. He then answers questions submitted by patients in attendance.
http://www.hss.edu/conditions_antiphospholipid-syndrome-education.asp
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS
Thursday, May 21, 2009
Volume 13 of the APSFA Newsletter - "Antiphospho...What?" is NOW Available!
Hello!!
The SPRING/SUMMER 2009 volume of our quarterly newsletter, "Antiphospho...What??" is ready to be downloaded. You can download it at the following link: http://www.apsfa.org/docs/APSFAVol13SprSum2009.pdf
The next volume will be coming out in late Summer, early Fall, 2009.
Please let us know if there are any topics that you'd like our Medical Advisors to cover in their articles. We try to request topics that people are emailing about or that are discussed on our the forum. So if there's anything you'd like to see, please let us know and we'll pass it along to the medical advisors.
We are still in need of patient stories (esp about Pregnancy Loss, Men and Teens or Children), recipes, poems, related book reviews, and anything else you think would be of interest for upcoming newsletters. (book reviews, poems, recipes, articles written by family members, etc.) Please submit articles to the following email address: articles@apsfa.org.
If you have an idea and are not sure if it would fit, please feel free to contact us through our contact page on the website, or email us using the email address below. We are open to any suggestions. Without your help we would not be able to include an APS patient's story in each of our newsletters.
Thank you to those people who have submitted articles. If you have submitted an article and we have not used it yet, we will be using it in the near future.
We could also use articles written by medical professionals or medical students. Please contact us if you are interested.
Please remember to check our website for any changes at the following link: http://www.apsfa.org/new.htm
Thank you for your continued support!
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS
Wednesday, April 15, 2009
Antiphospholipid Antibody Syndrome (APS) Workshop
Who: Hospital for Special Surgery
What: Antiphospholipid Antibody Syndrome (APS) Workshop
Where: 535 East 70th Street, New York City
When: Thursday April 30, 2009 from 6:00PM - 8PM EST
Why: APS can affect any organ, potentially causing blood clots, strokes, miscarriages, or other symptoms. It can occur alone or may be associated with an immune disorder like lupus.
For More Information: Call 212-774-7326
To Register: Click here: http://www.hss.edu/pped.asp
This one-session workshop provides an essential overview of diagnosis and treatment, and the opportunity to share your experiences with others coping with APS.
Speakers will be Michael Lockshin, MD and Jillian Rose, LMSW
The APS Foundation of America, Inc will have materials present.
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS
Thursday, April 09, 2009
New Cafe Press Graphics & Gear - Check It Out!
We just added several new designs in our CafePress store. If there's a design you like and it's not on an item (like a button, hat, sticker...etc) please email Heidii at heidi@apsfa.org and she will add it. Our Cafe Press Store is located here: http://www.cafepress.com/apsfoundation
100% of the profits from these products will go to the APS Foundation of America, Inc. APS Stands for Antiphospholipid Antibody Syndrome, which is a blood disorder that causes blood clots, strokes in young people and multiple miscarriages in women. The APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research and patient services in an effective and ethical manner. Thanks for looking!
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS
Tuesday, March 24, 2009
The Antiphospholipid Story
The Antiphospholipid Story
DONATO ALARCÓN-SEGOVIA, MD, MS, PhD,
Investigator,
Department of Immunology and Rheumatology,
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,
Vasco de Quiroga 15, 14000 Mexico DF, Mexico.
Address reprint requests to Dr. Alarcón-Segovia.
J Rheumatol. 2003 Sep;30(9):1893-6.
________________________________________
Throughout the history of humanity, and except for a few contributions by true pioneers, each bit of new knowledge or new development has been based on the work of many others, often unknown, who have helped build the corresponding edifice. Each milestone takes up so many yards, inches, centimeters, or millimeters according to the relative importance of the apparent new knowledge. However, the lack of even an apparently millimetric step, in this same sense, might prevent reaching the milestone. Stephenson may not have thought about it, but his invention of the railroad steam engine was only possible because throughout history people had learned to harness fire, including the unknown primitive humans who first learned to produce and keep it.
I will attempt to recount the saga of the antiphospholipid syndrome (APS), including my own experiences, with the precision of the scientist, the insight of one who has lived through it, and the emotion of one who sees in this story a wonderful example of the sum of contributions made for the sake of knowledge and helping fellow humans. Interest in this topic should not falter if we are to understand it fully, and with this understanding be able to provide our patients with a definitive solution.
I would like to take you as far back as 1906, to Wassermann and his coworkers1, who developed serological reactions for the diagnosis of syphilis utilizing phospholipid-rich tissues as antigens, later to be termed cardiolipin by Pangborn (1941)2. The finding of individuals who were positive for these reactions, but who were either too pious or too young to be suspected of having acquired syphilis, first brought about the possibility of false positive serological reactions for this disease, and tests were developed to distinguish these from the true positive reactions.
The first milestone resulted from the attempt to determine who, and perhaps why, some individuals had such false positive reactions for syphilis, and the finding that the majority were women who, when followed by Moore and Lutz (1955)3 for enough time, developed systemic lupus erythematosus (SLE). Interestingly, 3 of their 21 lupus patients with antecedent false positive tests for syphilis had had major unexplained thrombophlebitis. Here we should acknowledge the contributions, albeit indirect, of Hargraves, Richmond, and Morton (1948)4, who found LE cells that permitted a more ample diagnosis of SLE, and of Edmund Dubois (1953)5, who helped us recognize its wider clinical spectrum.
The second milestone resulted from the search for the cause of bleeding in a patient by Conley and Hartmann (1952)6, with the resulting finding of an inhibitor of coagulation that was subsequently related by Sánchez-Medal and Lisker (1959)7 from our own institute to patients with SLE, most of whom did not bleed.
The paradox encountered by Bowie and his coworkers (1963)8 of a frequent occurrence of thrombosis, rather than bleeding, in patients with SLE who had this inhibitor of coagulation, subsequently termed lupus anticoagulant by Feinstein and Rapaport (1977)9, marks the initiation of the concept of APS, particularly when somewhat later Thiagarajan, et al (1980)10, found that at least some of the lupus anticoagulants actually were antiphospholipid antibodies (aPL).
Shortly after the study of Bowie and his coworkers, and stemming from the same institution, Alarcón-Segovia and Osmundson (1965)11 described 11 patients with SLE who had peripheral vascular syndromes. Some of these are particularly interesting: one had chronic ulcers of the legs and livedo reticularis, clinical manifestations later found to be associated with aPL, and both circulating anticoagulant and false positive serologic tests for syphilis; another patient had had 4 miscarriages, thrombophlebitis, livedo reticularis, thrombosis of the left ulnar artery, convulsions, and long-standing false positive tests for syphilis; a third patient had false positive tests for syphilis, recurrent superficial thrombophlebitis, leg ulcers, intermittent claudication with evidence of popliteal artery occlusion, a vascular lesion of the brain stem, and a terminal occlusion of a basilar artery.
Shortly thereafter (1967) in a letter to Lancet, I insisted on the association of a circulating anticoagulant with infarction rather than bleeding12. Somewhat later (1974) Johansson and Lassus13 would indicate the concurrent findings of circulating anticoagulants and false positive tests for syphilis as in our described patient.
In 1980 Soulier and Boffa14 recorded the occurrence of recurrent abortions, thromboses, and a circulating anticoagulant in patients not having a primary condition, and in 1981 Carreras and his coworkers15 studied the possible role of inhibition of prostacyclin formation by the lupus anticoagulant in the causation of thrombosis.
The next milestones in the antiphospholipid story resulted from the development of more sensitive tests for aPL: in 1980 radioimmunoassays by Smolarsky16, by Harris and coworkers in 198317, and more practical, an ELISA developed by Loizou and his coworkers, using cardiolipin as antigen (1985)18. The more ample use of these tests permitted Hughes19 to propose the occurrence of an anticardiolipin syndrome in patients with SLE (1985). In some of his writings at that time Hughes mentioned that there were some patients with this syndrome who had no lupus, but he did not actually describe such patients.
The notion that within SLE there might be patients with a set of manifestations caused by one of their multiple autoantibodies and thus have a specific syndrome seemed interesting enough to me to try to confirm it. I therefore wrote Graham Hughes requesting some specific instructions on their anticardiolipin ELISA. I obtained a prompt response from Nigel Harris with instructions as well as anticardiolipin positive sera. Carmen Oria, a Venezuelan chemist working in our laboratory, was then able to reproduce the method, with modifications (1988)20. Meanwhile, with the help of Margarita Delezé, an enthusiastic rheumatologist who had come to our department after her hospital was destroyed in the 1985 Mexico City earthquake, we had started a cohort of consecutive lupus patients who were to be repeatedly tested for anticardiolipin antibodies. When the cohort reached 500 patients with a mean followup of more than 7 months and at least 5 antiphospholipid antibody tests of IgG, IgM, and/or IgA isotypes, we published our results21 confirming the existence of an APS in patients with SLE and documenting the clinical manifestations associated with high levels of aPL (1989). We would subsequently extend our cohort to 667 lupus patients, and after 3.5 years of followup, we proposed classification criteria for the APS (1992)22. Consensus criteria for the APS were later proposed (1999)23.
Analyzing our findings in the initial cohort of the 500 lupus patients, it became clear to me that there were patients who had the same clinical manifestations and high concentrations of anticardiolipin antibodies but who had no other clinical or serologic evidence of SLE. A search of the literature did not reveal any descriptions of this, although there were isolated reports of patients with some of these manifestations and those who had a circulating anticoagulant, as also described by Soulier and Boffa, whom we cited14.
With the help of Jorge Sánchez-Guerrero I prepared a description of 9 patients with what we termed primary antiphospholipid syndrome. Eventually, after some unexpected delays, on September 12, 1988, we submitted our manuscript to The Journal of Rheumatology; it was ultimately published early in 1989, and became one of its most highly cited articles24. At the end of 1988, however, Asherson published an editorial on the same topic in The Journal25. It was supposed to have accompanied our paper.
About 3 months later a paper by Mackworth-Young and coworkers appeared describing a series of patients with the same syndrome26, and later in the same year a larger multicenter series coordinated by Asherson was also published27. Our paper24 was already cited in their publication27. On July 5, 1993, Graham Hughes and I shared the Ciba-Geigy–International League Against Rheumatism Award, given to us at its international congress in Barcelona, for our contributions to knowledge on the APS.
A further milestone was reached in 1990 at the antiphospholipid meeting in Sirmione, Italy, when Monica Galli proposed that antibodies detected by ELISA tests with cardiolipin as antigen were not directed to the phospholipid but to a protein cofactor present in the bovine serum used to block the plates. This was supported by Steven Krilis, who had actually determined that the protein cofactor was ß2-glycoprotein-I (ß2-GPI), which had natural anticoagulant properties and high affinity for anionic molecules such as cardiolipin. Moreover, as noted by Takao Koike, pathogenic antibodies can be distinguished from those present in infectious disease (e.g., syphilis). The pathogenic antibodies require the presence of bovine serum with such cofactor, the infectious antibodies do not, he said. The corresponding articles were published that same year (1990)28-30.
At a ß2-GPI symposium in Milan in 1992, Cabral and his coworkers described the presence of anti-ß2-GPI antibodies in a group of patients with primary APS31; this finding was also published by Viard, et al that year32. That these antibodies may have the most important role in the causation of the APS, particularly its thrombotic component, was evidenced by their systematic fall at the time of thrombosis, as found by Gómez-Pacheco and coworkers33 in 1999.
An important study by Matsuura, Koike, and their coworkers34 (1995) revealed that the so-called anticardiolipin antibodies could bind to ß2-GPI in the absence of cardiolipin if the ELISA plates were oxidized by irradiation. This procedure was considered by Roubey and coworkers in 199535 to cause higher antigen density and permit bivalent binding. In 1995 Cabiedes, et al36 found that manifestations of APS associated more strongly with antibodies to ß2-GPI determined in non-irradiated plates versus those with anticardiolipin, and Cabral, myself, and our respective coworkers subsequently (1996, 1997)37 described groups of patients with clinical manifestations of APS who had persistently negative anticardiolipin antibodies when studied in conventional assays, but persistently positive anti-ß2-GPI antibodies determined in non-irradiated plates.
In 1988, early in the antiphospholipid story, I began inquiring about the pathogenic potential of aPL in an editorial38, and participated in a series of studies on their role in deficiencies of natural anticoagulants, headed by Guillermo and Alejandro Ruiz-Argüelles (1989)39, in a study by Vázquez-Mellado, et al (1994)40 on their role in thrombocytopenia by recognizing ß2-GPI that had bound to anionic phospholipids switched to the outer leaflet of platelets upon their activation or aggregation, as well as in a study by Cabral, et al41, where we found a role for an IgM natural autoantibody to phosphatidylcholine in the causation of hemolytic anemia (1990).
The synergism between aPL and antiendothelial cell antibodies in the causation of vascular damage in the APS began to be explored by Meroni and coworkers (1992)42, and a potential role of aPL in the causation of atherosclerosis stemmed from the seminal work by Vaarala and coworkers on the crossreactivity between anticardiolipin antibodies with oxidized low density lipoprotein (1993)43.
But perhaps the most important milestone for determining the pathogenicity of antiphospholipid antibodies came with the elegant series of studies by Shoenfeld and his group (1991)44,45, i.e., animal models of the APS induced both by passive and by active immunization, as well as their therapeutic manipulation (1999)46. In addition, these workers identified a hexapeptide that is recognized specifically by pathogenic anti-ß2-GPI antibodies and by antibodies produced on immunization of mice with microbial preparations. Naive mice infused with the antipeptide antibody produced by these immunizations developed clinical evidence of an antiphospholipid syndrome, indicating that molecular mimicry elicited by infections may lead to the development of pathogenic anti-ß2-GPI antibodies reactive with this peptide (2002)47.
The presence of autoreactive interleukin 6 producing CD4+ T cell clones to ß2-GPI in patients with APS was recently identified by Kuwana and his group (2001). These cells recognized at least 4 different epitopes, but the majority recognized a 15 amino acid peptide in the phospholipid-binding fifth domain. Most of these T cells stimulated autologous blood B cells to promote anti-ß2-GPI production in the presence of recombinant ß2-GPI. In a subsequent study they found that such autoreactive T cells had restricted T cell receptor ß-chain usage (Vß7 and Vß8) (2002)48.
Some of these findings may have implications regarding potential forms of treatment. Other avenues of treatment reside in the induction of tolerance of anti-ß2-GPI-producing B cells or in anionic blockade of the phospholipid-binding sites of ß2-GPI by means of heparin or other compounds, as proposed by Guerin and coworkers (2002)49.
Before the concept of an antiphospholipid syndrome originated, lupus patients with venous occlusions and particularly those with arterial occlusions were treated mainly with corticosteroids and immunosuppressives. In addition, patients with primary APS were often diagnosed as lupus and met classification criteria for this disease. This could have been considered reasonable were it not for the unnecessary steroid treatment they received instead of merely anticoagulant and/or platelet antiaggregant treatment.
We have come a long way in our understanding of the antiphospholipid syndrome. In looking back, I cannot help but feel that the wheels of the antiphospholipid story are turning more slowly, and at times even seem to stop. It might be only natural that the previous large scope of studies would now tend to be reduced. However, many unknowns await our renewed vigor. Only with vigor can we attain a brighter future for our patients.
REFERENCES
1. Wasserman A, Neisser A, Bruck C. Eine serodiagnostiche reaktion bei syphilis. Dtsch Med Wochenschr 1906;32:745-9.
2. Pangborn MC. A new serologically active phospholipid from beef heart. Proc Soc Exper Biol Med 1941;48:484-6.
3. Moore JE, Lutz WB. Natural history of systemic lupus erythematosus: approach to its study through chronic biologic false positive reactors. J Chron Dis 1955;1:297-316.
4. Hargraves MM, Richmond H, Morton R. Presentation of 2 bone marrow elements: the "Tart" cell and the "LE" cell. Proc Staff Meet Mayo Clin 1948;23:25-8.
5. Dubois EL. Effect of LE cell on clinical picture of systemic lupus erythematosus. Ann Intern Med 1953;93:1265-94.
6. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Lab Clin Invest 1952;31:621-2.
7. Sánchez-Medal L, Lisker R. Circulating anticoagulants in disseminated lupus erythematosus. Br J Haematol 1959;5:284-93.
8. Bowie EJ, Thompson JH Jr, Pascuzzi CA, Owen CA Jr. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963;62:416-30.
9. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemostas Thromb 1972;1:75-95.
10. Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of lupus anticoagulant. J Clin Invest 1980;66:397-405.
11. Alarcón-Segovia D, Osmundson PJ. Peripheral vascular syndromes associated with systemic lupus erythematosus. Ann Intern Med 1965;62:907-19.
12. Alarcón-Segovia D. Infarction and circulating anticoagulant. Lancet 1967;2:43-4.
13. Johansson EA, Lassus A. The occurrence of circulating anticoagulants in patients with syphilitic and biologically false positive antilipoidal antibodies. Ann Clin Res 1974;6:105-8.
14. Soulier JP, Boffa MC. Avortements á repetition, thromboses et anticoagulant circulant antithromboplastine. Nouv Presse Med 1980;9:859-64.
15. Carreras LO, Defreyn G, Machin SJ, et al. Arterial thrombosis, intrauterine death and "lupus" anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981;i:244-6.
16. Smolarsky MA. A simple radioimmunoassay to determine binding of antibodies to lipid antigens. J Immunol Methods 1980;38:85-93.
17. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;2:1211-4.
18. Loizou S, McCrea JD, Rudge A, Reynolds A, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985;62:738-45. [MEDLINE]
19. Hughes GRV. The anticardiolipin syndrome. Clin Exp Rheumatol 1985;3:285-6.
20. Delezé M, Oria CV, Alarcón-Segovia D. Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies. J Rheumatol 1988;15:611-5.
21. Alarcón-Segovia D, Delezé M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353-65.
22. Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992;21:275-85.
23. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
24. Alarcón-Segovia D, Sánchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989;16:482-8.
25. Asherson RA. A "primary" antiphospholipid syndrome? J Rheumatol 1988;15:1742-6.
26. Mackworth-Young CG, Loizou S, David J, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989;48:362-7.
27. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989;68:366-74.
28. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
29. McNeil HD, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta-2- glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
30. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-8.
31. Shoenfeld Y, Meroni PL. The beta-2-glycoprotein I and antiphospholipid antibodies. Clin Exp Rheumatol 1992;10:205-9.
32. Viard JP, Amoura Z, Bach JF. Association of anti-beta2- glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992;93:181-6.
33. Gómez-Pacheco L, Villa AR, Drenkard C, Cabiedes J, Cabral AR, Alarcón-Segovia D. Serum anti-beta 2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med 1999;106:417-23.
34. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457-62.
35. Roubey RAS, Eisenberg R, Harper MF, Winfield JB. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995;154:954-60.
36. Cabiedes J, Cabral AR, Alarcón-Segovia D. Clinical manifestations of the antiphospholipid syndrome in systemic lupus erythematosus patients associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22:1899-906.
37. Alarcon-Segovia D, Cabral AR. Antiphospholipid/cofactor syndromes. J Rheumatol 1996;23:1319-22.
38. Alarcon-Segovia D. Pathogenetic potential of antiphospholipid antibodies. J Rheumatol 1988;15:890-3.
39. Ruiz-Arguelles GJ, Ruíz-Argüelles A, Alarcón-Segovia D, et al. Natural anticoagulants in systemic lupus erythematosus. Deficiency of protein S bound to C4bp with recent history of venous thromboses, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheumatol 1991;18:552-8.
40. Vazquez-Mellado J, Llorente L, Alarcón-Segovia D. Exposure of anionic phospholipid upon platelet activation permits binding of beta 2-glycoprotein-I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J Autoimmun 1994;7:335-48.
41. Cabral AR, Cabiedes J, Alarcón-Segovia D. Hemolytic anemia related to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to bromelain-treated human erythrocytes. J Autoimmun 1990;3:773-87.
42. Del Papa N, Meroni PL, Tincani A, et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells. Clin Exp Rheumatol 1992;10:37-42.
43. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-5.
44. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome by passive transfer of anti-cardiolipin antibodies. Proc Nat Acad Sci USA 1991;88:3069-73.
45. Blank M, Faden D, Tincani A, et al. Immunization with anticardiolipin cofactor (beta 2 GP-I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994;7:441-55.
46. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Nat Acad Sci USA 1999;96:5164-8.
47. Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta 2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109:797-804.
48. Yoshida K, Arai T, Kaburaki J, Ikeda Y, Kawakami Y, Kuwana M. Restricted T-cell receptor beta-chain usage by T cells autoreactive to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2002;99:2499-504.
49. Guerin J, Sheng Y, Reddel S, Iverson GM, Chapman MG, Krilis S. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. J Biol Chem 2002;277:1-6.
Thursday, March 19, 2009
March is Deep Vein Thrombosis (DVT) Awareness Month
March is Deep Vein Thrombosis (DVT) Awareness Month
Click on this banner to watch the video:
or you can watch this here: http://www.youtube.com/watch?v=RUYI6Xju4RA
For DVT related awareness gear go to http://www.cafepress.com/apsfoundation.
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS
Monday, March 02, 2009
Volume 12 of the APSFA Newsletter - "Antiphospho...What?" is NOW Available!
Volume 12 of the APSFA Newsletter - "Antiphospho...What?" is NOW Available!
Hello!!
The WINTER/SPRING 2009 volume of our quarterly newsletter, "Antiphospho...What??" is ready to be downloaded. You can download it at the following link: http://www.apsfa.org/docs/APSFAVol12WinSpr2009.pdf
The next volume will be coming out in late Spring, early Summer, 2009.
Please let us know if there are any topics that you'd like our Medical Advisors to cover in their articles. We try to request topics that people are emailing about or that are discussed on our the forum. So if there's anything you'd like to see, please let us know and we'll pass it along to the medical advisors.
We are still in need of patient stories (esp about Pregnancy Loss, Men and Teens or Children), recipes, poems, related book reviews, and anything else you think would be of interest for upcoming newsletters. (book reviews, poems, recipes, articles written by family members, etc.) Please submit articles to the following email address: articles@apsfa.org.
If you have an idea and are not sure if it would fit, please feel free to contact us through our contact page on the website, or email us using the email address below. We are open to any suggestions. Without your help we would not be able to include an APS patient's story in each of our newsletters.
Thank you to those people who have submitted articles. If you have submitted an article and we have not used it yet, we will be using it in the near future.
We could also use articles written by medical professionals or medical students. Please contact us if you are interested.
Please remember to check our website for any changes at the following link: http://www.apsfa.org/new.htm
Thank you for your continued support!
Keywords: APSFA, APS Foundation, antiphospholipid antibody syndrome, lupus, stroke, dvt, pe, thrombosis, clot, migraine, hughes syndrome, miscarriage, america, usa, anticoagulant, heart attack, APS, newsletter
Subscribe to:
Posts (Atom)
